2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

被引：288
|
作者：
Das, Sandeep R. [1 ]
Everett, Brendan M. [2 ]
Birtcher, Kim K. [3 ]
Brown, Jenifer M. [4 ]
Januzzi, James L., Jr. [5 ]
Kalyani, Rita R. [6 ]
Kosiborod, Mikhail [7 ,8 ]
Magwire, Melissa [9 ]
Morris, Pamela B. [10 ,11 ]
Neumiller, Joshua J. [12 ,13 ]
Sperling, Laurence S. [14 ,15 ,16 ]
机构：
[1] UT Southwestern Med Ctr, Med, Dallas, TX 75390 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Houston, Coll Pharm, Houston, TX 77004 USA
[4] Brigham & Womens Hosp, Cardiol, Boston, MA 02115 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Med, Boston, MA 02115 USA
[6] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21218 USA
[7] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[8] Univ Missouri Kansas City, Med, Kansas City, MO USA
[9] St Lukes Hlth Syst, Cardiometabol Ctr Alliance, Kansas City, MO USA
[10] Med Univ South Carolina, Seinsheimer Cardiovasc Hlth Program, Columbia, SC USA
[11] Med Univ South Carolina, Womens Heart Care, Columbia, SC USA
[12] Washington State Univ, Pullman, WA 99164 USA
[13] Washington State Univ, Pharmacotherapy, Pullman, WA 99164 USA
[14] Emory Heart Dis Prevent Ctr, Med Cardiol, Atlanta, GA USA
[15] Emory Univ, Atlanta, GA 30322 USA
[16] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Global Hlth, Atlanta, GA 30322 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 76卷 / 09期
关键词：
ACC Expert Consensus Decision Pathway; atherosclerotic cardiovascular disease; cardiovascular risk reduction; diabetes; GLP-1RA; SGLT2; inhibitor; type; 2; PEPTIDE-1 RECEPTOR AGONISTS; ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; HEART-FAILURE; 2019; METHODOLOGY; GLUCOSE CONTROL; DOUBLE-BLIND; EMPAGLIFLOZIN; DISEASE; OUTCOMES;
D O I：
10.1016/j.jacc.2020.05.037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1117 / 1145
页数：29
相关论文
共 50 条
  • [21] 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
    Lloyd-Jones, Donald M.
    Morris, Pamela B.
    Ballantyne, Christie M.
    Birtcher, Kim K.
    Daly, David D., Jr.
    DePalma, Sondra M.
    Minissian, Margo B.
    Orringer, Carl E.
    Smith, Sidney C., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (14) : 1785 - 1822
  • [22] Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Tan, Jack Wei Chieh
    Sim, David
    Ako, Junya
    Almahmeed, Wael
    Cooper, Mark E.
    Dalal, Jamshed J.
    Deerochanawong, Chaicharn
    Huang, David Wei Chun
    Johar, Sofian
    Kaul, Upendra
    Kim, Sin Gon
    Koh, Natalie
    Kong, Alice Pik-Shan
    Krittayaphong, Rungroj
    Kwok, Bernard
    Matawaran, Bien J.
    Quang Ngoc Nguyen
    Ong, Loke Meng
    Park, Jin Joo
    Peng, Yongde
    Quek, David K. L.
    Suastika, Ketut
    Sukor, Norlela
    Teo, Boon Wee
    Teoh, Chee Kiang
    Zhang, Jian
    Reyes, Eugenio B.
    Goh, Su Yen
    EUROPEAN CARDIOLOGY REVIEW, 2021, 16
  • [23] Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes
    Sabbour, Hani
    Almahmeed, Wael
    Alawadi, Fatheya
    Shehab, Abdullah
    Al Zubaidi, Abdulamjeed
    Bashier, Alaaeldin
    Ghulam, Abdul Rauf
    Rashid, Fauzia
    Zaky, Hosam
    Heshmat Kassemn, Hussien
    Adi, Jamila Bin
    Tahir, Juwairia
    Hafidh, Khadija
    Farghali, Mohammed
    Hassanien, Mohamed
    Januzzi, James
    FRONTIERS IN ENDOCRINOLOGY, 2025, 15
  • [24] GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
    Marx, Nikolaus
    Husain, Mansoor
    Lehrke, Michael
    Verma, Subodh
    Sattar, Naveed
    CIRCULATION, 2022, 146 (24) : 1882 - 1894
  • [25] Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes JACC Guideline Comparison
    Kelsey, Michelle D.
    Nelson, Adam J.
    Green, Jennifer B.
    Granger, Christopher B.
    Peterson, Eric D.
    McGuire, Darren K.
    Pagidipati, Neha J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (18) : 1849 - 1857
  • [26] Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk
    Nguyen, Elaine
    Coleman, Craig I.
    Nair, Suresh
    Weeda, Erin R.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2018, 32 (02) : 210 - 215
  • [27] Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes
    Martins, Eduardo Bello
    Lima, Eduardo Gomes
    Pitta, Fabio Grunspun
    Solon Carvalho, Leticia Neves
    de Queiroz, Thiago Dias
    Serrano Junior, Carlos Vicente
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (09): : 1283 - 1288
  • [28] The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study
    Shin, Sooyoung
    Kim, Hyunah
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 435 - 444
  • [29] Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease
    Zhang, Fang
    Ji, Linong
    Hong, Tianpei
    Guo, Lixin
    Li, Yan
    Zhu, Zhiming
    Liu, Xingbin
    Liu, Fang
    Tang, Lizhi
    Zhang, Yuwei
    Li, Juan
    Lu, Qingguo
    Tong, Nanwei
    JOURNAL OF EVIDENCE BASED MEDICINE, 2022, 15 (02) : 168 - 179
  • [30] AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus
    Berra, Cesare
    Manfrini, Roberto
    Mirani, Marco
    Bucciarelli, Loredana
    Zakaria, Ahmed S.
    Piccini, Sara
    Ghelardi, Renata
    Lunati, Maria Elena
    Rodovalho, Sylka
    Bifari, Francesco
    Fiorina, Paolo
    Folli, Franco
    ACTA DIABETOLOGICA, 2023, 60 (09) : 1257 - 1266
12345